Vertex unveils promising data on new cystic fibrosis drugs as sales top $2B

Vertex Pharmaceuticals Inc. said Wednesday that sales of its two approved cystic fibrosis drugs jumped 29 percent in 2017 to nearly $2.2 billion. And yet those jaw-dropping figures might be eclipsed by another, from ongoing studies of the Boston-based company ’s next generation of treatments. Vertex (Nasdaq: VRTX) reported data from mid-stage trials of two experimental drug cocktails that the company believes could help nearly all patients with the lung disease. According to Vertex, patients in…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news